MEI Pharma, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Justin J. File CPA
- Full Time Employees
- 28
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 11455 El Camino Real San Diego CA United States of America 92130
- IPO Date
- Dec 18, 2003
- CIK
- 0001262104
- Website
- meipharma.com
- Similar Companies
- Business
- Lite Strategy, Inc. (NASDAQ: LITS), formerly MEI Pharma, Inc., operates as the first U.S.-listed public company to adopt Litecoin as its primary treasury reserve asset through active digital asset management strategies; it maintains a clinical-stage pharmaceutical pipeline focused on novel cancer therapies intended to overcome drug resistance mechanisms in combination with standard-of-care treatments. The company's core offerings encompass treasury management of Litecoin (LTC) holdings, currently comprising 929,548 LTC tokens acquired at an average price of $107.58 and valued at approximately $110.4 million as of August 2025; pharmaceutical drug candidates including voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor evaluated in combination with venetoclax for relapsed/refractory acute myeloid leukemia and explored preclinically for solid tumors, ME-344 (now WE-868, sold to Aardvark Therapeutics for obesity development), zandelisib, an oral selective PI3Kδ inhibitor, and eganelisib, an oral immuno-oncology macrophage reprogramming agent planned for Phase 2 trials in head and neck squamous cell carcinoma with pembrolizumab. Founded in 2000 and headquartered in San Diego, California, Lite Strategy targets institutional investors seeking compliant Litecoin exposure alongside oncology innovation, with operations centered in the United States. Recent developments include a $100 million private placement in July 2025 to initiate Litecoin accumulation in partnership with GSR and under guidance from Litecoin creator Charlie Lee, who joined the board; rebranding from MEI Pharma to Lite Strategy in September 2025 with a new ticker (LITS) and website (litestrategy.com); sale of the ME-344 asset; a $25 million share repurchase program announced in October 2025 to optimize LTC treasury value; and expansion into active capital market operations while evaluating remaining pharma assets.
MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS'
BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven mode
MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
Why Is MEI Pharma Stock Soaring On Friday?
MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position
MEI Pharma Reports Fiscal Year End 2024 Cash Position
MEI Pharma to Consider Strategic Alternatives
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
National Bank of Canada FI Takes $36,000 Position in MEI Pharma, Inc. (NASDAQ:MEIP)
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)